# Study of FG-4592 in Subjects With End-Stage Renal Disease Receiving Maintenance Hemodialysis in China

> **NCT01596855** · PHASE2 · COMPLETED · sponsor: **Kyntra Bio** · enrollment: 96 (actual)

## Conditions studied

- Anemia in End Stage Renal Disease

## Interventions

- **DRUG:** FG-4592
- **DRUG:** Epoetin Alfa

## Key facts

- **NCT ID:** NCT01596855
- **Lead sponsor:** Kyntra Bio
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-09
- **Primary completion:** 2013-01
- **Final completion:** 2013-01
- **Target enrollment:** 96 (ACTUAL)
- **Last updated:** 2013-02-04

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01596855

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01596855, "Study of FG-4592 in Subjects With End-Stage Renal Disease Receiving Maintenance Hemodialysis in China". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01596855. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*